Abstract:OBJECTIVE:Tacrolimus is used clinically for the long-term treatment of antirejection of transplanted organs in liver and kidney transplant recipients, although dose optimization is poorly managed. The aim of this study was to examine the association between tacrolimus pharmacokinetic variability and CYP3A4 and CYP3A5 genotypes by a population pharmacokinetic analysis based on routine drug monitoring data in adult renal transplant recipients.MATERIALS AND METHODS:Trough tacrolimus concentrations were obtained from 161 adult kidney transplant recipients after transplantation. The population pharmacokinetic analysis was carried out using the nonlinear mixed-effect modeling software NONMEM version 7.2. The CYP3A4*1G and CYP3A5*3 genetic polymorphisms from the patients studied were determined by direct sequencing using a validated automated genetic analyzer.RESULTS:A one-compartment model with first-order absorption and elimination adequately described the pharmacokinetics of tacrolimus. Covariates including CYP3A5*3 and CYP3A4*1G alleles and hematocrit were retained in the final model. The apparent clearance of tacrolimus was about two-fold higher in kidney transplant patients with higher enzymatic activity of CYP3A5*1 and CYP3A4*1G (with the CYP3A5*1/*1 or *1/*3 and CYP3A4*1/*1G or CYP3A4*1G/*1G) compared with those with lower enzymatic activity (CYP3A5*3/*3 and CYP3A4*1/*1).CONCLUSION:This is the first study to extensively determine the effect of CYP3A4*1G and CYP3A5*3 genetic polymorphisms and hematocrit value on tacrolimus pharmacokinetics in Chinese renal transplant recipients. The findings suggest that CYP3A5*3 and CYP3A4*1G polymorphisms and hematocrit are determinant factors in the apparent clearance of tacrolimus. The initial dose design is mainly based on CYP3A5 and CYP3A4 genotypes as well as hematocrit. This result may also be useful for maintenance tacrolimus dose optimization and may help to avoid fluctuating tacrolimus levels and improve the efficacy and tolerability of tacrolimus in kidney transplant recipients.

Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome.

Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients

Effects of CYP3A4 and CYP3A5 Polymorphisms on Tacrolimus Pharmacokinetics in Chinese Adult Renal Transplant Recipients: a Population Pharmacokinetic Analysis.

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

The Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

Influence Ofcyp3a5genotypes on Tacrolimus Dose Requirement: Age and Its Pharmacological Interaction Withabcb1genetics in the Chinese Paediatric Liver Transplantation

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

Influences of ABCB1 polymorphism on the dose adjusted blood concentration of tacrolimus and renal function in renal transplant recipients with cytochrome P450 3A5 * 3/* 3 genotype

Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients

Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis

Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients

Kidney Podocyte-Associated Gene Polymorphisms Affect Tacrolimus Concentration in Pediatric Patients with Refractory Nephrotic Syndrome.

CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.

Effect of CYP3A5 Polymorphism on the Pharmacokinetics of Tacrolimus and Acute Rejection in Renal Transplant Recipients: Experience at a Single Centre.

Association Of Cyp3a4*18b Polymorphisms With The Pharmacokinetics Of Tacrolimus In Chinese Renal Transplant Recipients

CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation